Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Denovo Starts US-China Phase III Study of Lymphoma Treatment

publication date: Apr 5, 2018

Denovo Biopharma, a San Diego-Hangzhou company,  has started a pivotal Phase III trial of its lead drug, DB102 (enzastaurin). DB102, which was initially developed by Eli Lilly, failed a Phase III clinical trial in 2013 in patients with diffuse large B-cell lymphoma (DLBCL). Denovo acquired global rights to DB102 in 2014, planning to redevelop the drug by targeting a sub-set of patients. By analyzing Lilly’s patient samples, Denovo found overall survival was significantly improved for patients who possess the DGM1 biomarker. The study will enroll 235 patients in the US and China. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here